ARS Pharma reports Q1 revenue $22.7M, neffy net product revenue $17.5M

ARS Pharmaceuticals, Inc.

2026-Q1 EPS reported -$0.61 revenue$22,681,000

Net loss $60.6M ($0.61/share); cash $201M; expects to fund to cash-flow break-even.
CVS Caremark formulary proposal in final stages; target July 1, 2026; gross-to-net target ~50%.
Sales force expanded to 148 reps; SG&A $72.2M includes DTC marketing investment.
Health Canada approved neffy on April 15; EU 1 mg dose approved for children 4+ years.
Phase 2b CSU trial interim population fully enrolled; data expected Q4 2026.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.